Monopar Therapeutics (MNPR) director receives 7,710 common shares via distribution

Rhea-AI Filing Summary

Monopar Therapeutics director reported receiving additional company shares in an insider transaction. On 12/16/2025, the reporting person acquired 7,710 shares of Monopar Therapeutics common stock at a stated price of $0, coded as transaction type J. After this transaction, the reporting person beneficially owned 13,883 shares, held directly.

According to the explanation provided, the shares were received through a pro rata distribution from Gem Pharmaceuticals, LLC, in which the reporting person is a non-managing member. The filing indicates it was submitted for one reporting person in their capacity as a director of Monopar Therapeutics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KLAUSNER ARTHUR J

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE IL 60091

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		J(1)		7,710	A	$0	13,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pro rata distribution from Gem Pharmaceuticals, LLC, of which the reporting person is a non-managing member.

	/s/ Quan Vu, Attorney-in-fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Monopar Therapeutics (MNPR) report on this Form 4?

The filing reports that a director of Monopar Therapeutics acquired 7,710 shares of common stock in a transaction dated 12/16/2025, recorded under transaction code J.

How many Monopar Therapeutics (MNPR) shares does the insider own after the reported transaction?

Following the reported transaction, the director beneficially owned 13,883 shares of Monopar Therapeutics common stock, held in direct ownership.

What was the price and nature of the Monopar Therapeutics (MNPR) shares acquired?

The director acquired 7,710 shares of Monopar Therapeutics common stock at a stated price of $0 per share, classified as transaction code J, which indicates an "other" type of transaction.

What is the source of the Monopar Therapeutics (MNPR) shares received by the director?

The explanation states the shares came from a pro rata distribution from Gem Pharmaceuticals, LLC, an entity in which the reporting person is described as a non-managing member.

What is the insider’s relationship to Monopar Therapeutics (MNPR)?

The reporting person is identified in the filing as a Director of Monopar Therapeutics and is not marked as a 10% owner or officer in this report.

Was this Monopar Therapeutics (MNPR) Form 4 filed for multiple insiders?

No. The document indicates it is a Form filed by one reporting person, not a joint filing by multiple insiders.